HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Beneficial effects of angiotensin-(1-7) against deoxycorticosterone acetate-induced diastolic dysfunction occur independently of changes in blood pressure.

Abstract
Mineralocorticoids have been implicated in the pathogenesis of diastolic heart failure. On the contrary, angiotensin (Ang)-(1-7) has emerged as a potential strategy for treatment of cardiac dysfunction induced by excessive mineralocorticoid receptor activation. A critical question about the cardioprotective effect of Ang-(1-7) in hypertensive models is its dependence on blood pressure (BP) reduction. Here, we addressed this question by investigating the mechanisms involved in Ang-(1-7) cardioprotection against mineralocorticoid receptor activation. Sprague-Dawley (SD) and transgenic (TG) rats that overexpress an Ang-(1-7) producing fusion protein (TG(A1-7)3292) were treated with deoxycorticosterone acetate (DOCA) for 6 weeks. After treatment, SD rats became hypertensive and developed ventricular hypertrophy. These parameters were attenuated in TG-DOCA. SD-DOCA rats developed diastolic dysfunction which was associated at the cellular level with reduced Ca(2+) transient. Oppositely, TG-DOCA myocytes presented enhanced Ca(2+) transient. Moreover, higher extracellular signal-regulated kinase phosphorylation, type 1 phosphatase, and protein kinase Cα levels were found in SD-DOCA cells. In vivo, pressor effects of DOCA can contribute to the diastolic dysfunction, raising the question of whether protection in TG was a consequence of reduced BP. To address this issue, BP in SD-DOCA was kept at TG-DOCA level by giving hydralazine or by reducing the DOCA amount given to rats (Low-DOCA). Under similar BP, diastolic dysfunction and molecular changes were still evident in DOCA-hydralazine and SD-low-DOCA, but not in TG-DOCA. In conclusion, Ang-(1-7) protective signaling against DOCA-induced diastolic dysfunction occurs independently of BP attenuation and is mediated by the activation of pathways involved in Ca(2+) handling, hypertrophy, and survival.
AuthorsPedro W Machado de Almeida, Marcos Barrouin Melo, Ricardo de Freitas Lima, Mariana Gavioli, Nivia M Santiago, Leonardo Greco, Itamar C G Jesus, Eduardo Nocchi, Amanda Parreira, Marcia N M Alves, Luciana Mitraud, Rodrigo Ribeiro Resende, Maria José Campagnole-Santos, Robson Augusto Souza Dos Santos, Silvia Guatimosim
JournalHypertension (Dallas, Tex. : 1979) (Hypertension) Vol. 66 Issue 2 Pg. 389-95 (Aug 2015) ISSN: 1524-4563 [Electronic] United States
PMID26077567 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Copyright© 2015 American Heart Association, Inc.
Chemical References
  • Peptide Fragments
  • Hydralazine
  • Desoxycorticosterone Acetate
  • Angiotensin I
  • angiotensin I (1-7)
  • Calcium
Topics
  • Angiotensin I (pharmacology, therapeutic use)
  • Animals
  • Blood Pressure (drug effects, physiology)
  • Calcium (physiology)
  • Calcium Signaling (drug effects, physiology)
  • Desoxycorticosterone Acetate (adverse effects)
  • Disease Models, Animal
  • Dose-Response Relationship, Drug
  • Heart Failure, Diastolic (chemically induced, physiopathology, prevention & control)
  • Hydralazine (pharmacology)
  • Hypertension (physiopathology)
  • Male
  • Peptide Fragments (pharmacology, therapeutic use)
  • Rats
  • Rats, Sprague-Dawley
  • Rats, Transgenic

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: